These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29770976)

  • 1. Pharmacokinetic and pharmacodynamic properties of orally administered torsemide in healthy horses.
    Agne GF; Jung SW; Wooldridge AA; Duran SH; Ravis W; Toribio R
    J Vet Intern Med; 2018 Jul; 32(4):1428-1435. PubMed ID: 29770976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effect of torsemide in a horse with congestive heart failure and atrial fibrillation.
    Ferlini Agne G; Kapusniak AE; Wooldridge AA; Jung SW
    J Equine Vet Sci; 2024 Feb; 133():105001. PubMed ID: 38190865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of oral administration of furosemide and torsemide in healthy dogs.
    Hori Y; Takusagawa F; Ikadai H; Uechi M; Hoshi F; Higuchi S
    Am J Vet Res; 2007 Oct; 68(10):1058-63. PubMed ID: 17916010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis.
    Schwartz S; Brater DC; Pound D; Green PK; Kramer WG; Rudy D
    Clin Pharmacol Ther; 1993 Jul; 54(1):90-7. PubMed ID: 8330470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure.
    Gottlieb SS; Khatta M; Wentworth D; Roffman D; Fisher ML; Kramer WG
    Am J Med; 1998 Jun; 104(6):533-8. PubMed ID: 9674715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Torsemide: a pyridine-sulfonylurea loop diuretic.
    Blose JS; Adams KF; Patterson JH
    Ann Pharmacother; 1995 Apr; 29(4):396-402. PubMed ID: 7633019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic properties of orally administered torasemide in healthy cats.
    Roche-Catholy M; Paepe D; Devreese M; Broeckx BJG; Woehrlé F; Schneider M; de Salazar Alcala AG; Hellemans A; Smets P
    J Vet Intern Med; 2022 Sep; 36(5):1782-1791. PubMed ID: 35906901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacodynamics of torsemide in patients with congestive heart failure.
    Vargo D; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC
    Clin Pharmacol Ther; 1994 Jul; 56(1):48-54. PubMed ID: 8033494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency.
    Gehr TW; Rudy DW; Matzke GR; Kramer WG; Sica DA; Brater DC
    Clin Pharmacol Ther; 1994 Jul; 56(1):31-8. PubMed ID: 8033492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of torsemide in patients with decompensated and compensated congestive heart failure.
    Bleske BE; Welage LS; Kramer WG; Nicklas JM
    J Clin Pharmacol; 1998 Aug; 38(8):708-14. PubMed ID: 9725546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Torsemide: a new loop diuretic.
    Fowler SF; Murray KM
    Am J Health Syst Pharm; 1995 Aug; 52(16):1771-80; quiz 1814-5. PubMed ID: 8528833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.
    Vargo DL; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC
    Clin Pharmacol Ther; 1995 Jun; 57(6):601-9. PubMed ID: 7781259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between the effects of torsemide and furosemide on the renin-angiotensin-aldosterone system of normal dogs.
    Potter BM; Ames MK; Hess A; Poglitsch M
    J Vet Cardiol; 2019 Dec; 26():51-62. PubMed ID: 31809955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group.
    Patterson JH; Adams KF; Applefeld MM; Corder CN; Masse BR
    Pharmacotherapy; 1994; 14(5):514-21. PubMed ID: 7997385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.
    Vormfelde SV; Engelhardt S; Zirk A; Meineke I; Tuchen F; Kirchheiner J; Brockmöller J
    Clin Pharmacol Ther; 2004 Dec; 76(6):557-66. PubMed ID: 15592327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure.
    Kramer WG; Smith WB; Ferguson J; Serpas T; Grant AG; Black PK; Brater DC
    J Clin Pharmacol; 1996 Mar; 36(3):265-70. PubMed ID: 8690821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of torsemide and furosemide on clinical, laboratory, radiographic and quality of life variables in dogs with heart failure secondary to mitral valve disease.
    Peddle GD; Singletary GE; Reynolds CA; Trafny DJ; Machen MC; Oyama MA
    J Vet Cardiol; 2012 Mar; 14(1):253-9. PubMed ID: 22364690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients.
    Vargas Hein O; Staegemann M; Wagner D; von Heymann C; Martin M; Morgera S; Spies C
    Ren Fail; 2005; 27(4):385-92. PubMed ID: 16060124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency.
    Rudy DW; Gehr TW; Matzke GR; Kramer WG; Sica DA; Brater DC
    Clin Pharmacol Ther; 1994 Jul; 56(1):39-47. PubMed ID: 8033493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease.
    Vasavada N; Saha C; Agarwal R
    Kidney Int; 2003 Aug; 64(2):632-40. PubMed ID: 12846760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.